IRB #

IRB00011256

Title

Phase 2 Study of Preoperative Chemotherapy with Abraxane and Gemcitabine Followed by Chemoradiation for Borderline Resectable or Node-Positive Pancreatic Cancer

Principal Investigator

Gina Vaccaro

Study Purpose

The study is being done to determine the resection rate for subjects with pancreatic cancer after receiving gemcitabine, abraxane, 5-FU and radiation therapy.

Medical Condition(s)

Pancreatic cancer

Eligibility Criteria

1. Male or female age 18 or older
2. Confirmed adenocarcinoma of the pancreas
3. Tumors must be localized (not spread to other organs) and classified as borderline-resectable
4. No prior therapy for pancreatic cancer
5. Other criteria apply

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

Treatment may continue until disease progression, unacceptable side effects, or withdrawal from the study. Follow-up will last for 5 years after last treatment.

Minors Included

No

Contact

Knight Clinical Trials Information Line
503-494-1080

Sponsor

OHSU Knight Cancer Institute

Recruitment End

12/31/2022

Compensation Provided

No


Go Back